0.267

54.20% -0.316

After Hours: .27 0.003 +1.12%

Moleculin Biotech Inc (MBRX)

Overview News Price History Financials Discussions Forecast Stock Split

Moleculin Biotech Inc stock is traded at $0.267, with a volume of 16.25M. It is down -54.20% in the last 24 hours and down -72.75% over the past month. Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Previous Close:

$0.583

Open:

$0.27375

24h Volume:

16.25M

Relative Volume:

27.87

Market Cap:

$9.35M

Revenue:

Net Income/Loss:

$-29.77M

P/E Ratio:

-0.0175

EPS:

-15.2954

Net Cash Flow:

$-24.23M

1W Performance:

-58.41%

1M Performance:

-72.75%

6M Performance:

-84.01%

1Y Performance:

-92.94%

1-Day Range:

$0.25

$0.3431

1-Week Range:

$0.25

$0.7262

52-Week Range:

$0.25

$4.707

Moleculin Biotech Inc Stock (MBRX) Company Profile

Name

Moleculin Biotech Inc

Sector

Healthcare (1175)

Industry

Biotechnology (661)

Phone

713-300-5160

Address

5300 MEMORIAL DRIVE, HOUSTON, TX

Employee

Twitter

@moleculinbio

Next Earnings Date

2024-12-08

Latest SEC Filings

MBRX's Discussions on Twitter

Compare MBRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MBRX Moleculin Biotech Inc	0.267	9.35M	0	-29.77M	-24.23M	-15.30
VRTX Vertex Pharmaceuticals Inc	440.87	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	509.72	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	309.70	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	542.15	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	247.08	28.51B	3.81B	-644.79M	-669.77M	-6.24

Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-09-25	Resumed	H.C. Wainwright	Buy
Feb-12-25	Downgrade	Maxim Group	Buy → Hold
Jul-18-22	Resumed	Oppenheimer	Outperform

Moleculin Biotech Inc Stock (MBRX) Latest News

Jun 18, 2025

Moleculin Biotech (MBRX) Rating Reiterated with $4.00 Price Target | MBRX Stock News - GuruFocus

Jun 18, 2025

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan - GuruFocus

Jun 18, 2025

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML - GlobeNewswire

Jun 18, 2025

Moleculin Participates in Virtual Investor “What This Means” Seg - GuruFocus

Jun 18, 2025

Moleculin Biotech’s Annamycin Pediatric Study Approved by FDA - TipRanks

Jun 18, 2025

Moleculin Participates in Virtual Investor “What This Means” Segment - GlobeNewswire

Jun 18, 2025

Moleculin Biotech (MBRX) Advances Pediatric Cancer Treatment Study | MBRX Stock News - GuruFocus

Jun 18, 2025

Moleculin Receives Critical FDA Support for Children's Leukemia Treatment Development - Stock Titan

Jun 18, 2025

Moleculin Biotech, Inc. Advances Annamycin for Pediatric Cancer Treatment as FDA Approves Inclusion of Younger Patients in Clinical Study - Nasdaq

Jun 18, 2025

FDA agrees to Moleculin’s pediatric study plan for cancer drug - Investing.com

Jun 18, 2025

Jun 12, 2025

Moleculin Biotech announces ‘What This Means’ virtual investor segment - Yahoo Finance

Jun 12, 2025

What is HC Wainwright’s Estimate for MBRX Q2 Earnings? - Defense World

Jun 12, 2025

Jun 11, 2025

Moleculin Biotech (MBRX) Reports Positive Results from Annamycin Trial | MBRX Stock News - GuruFocus

Jun 11, 2025

Moleculin Participates in Virtual Investor “What This Means” Segment | MBRX Stock News - GuruFocus

Jun 11, 2025

Moleculin Biotech, Inc. Reports Positive Topline Results from Phase 1B/2 Trial of Annamycin for Soft Tissue Sarcoma Lung Metastases - Nasdaq

Jun 11, 2025

Research Analysts Offer Predictions for MBRX Q4 Earnings - Defense World

Jun 11, 2025

Jun 10, 2025

Moleculin Biotech (NASDAQ:MBRX) Stock Rating Upgraded by HC Wainwright - Defense World

Jun 10, 2025

Jun 09, 2025

Moleculin Biotech (MBRX) Receives "Buy" Rating and $4.00 Price Target | MBRX Stock News - GuruFocus

Jun 09, 2025

Moleculin Biotech Reports Positive Annamycin Trial Results - MSN

Jun 09, 2025

Moleculin Biotech (MBRX) Receives Buy Rating and $4 Price Target | MBRX Stock News - GuruFocus

Jun 09, 2025

Jun 05, 2025

Moleculin Biotech Stock (MBRX) Dives 10% on Clinical Trial Results - The Globe and Mail

Jun 05, 2025

Moleculin Releases On-Demand KOL Webcast to Discuss Data - GlobeNewswire

Jun 05, 2025

Transcript : Moleculin Biotech, Inc.Pre Recorded Shareholder/Analyst Call - MarketScreener

Jun 05, 2025

Moleculin Biotech, Inc. Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) - MarketScreener

Jun 05, 2025

Moleculin Biotech Hosts Key Opinion Leaders Event - TipRanks

Jun 05, 2025

Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow

Jun 05, 2025

Moleculin Biotech (MBRX) Presents Final Data from Annamycin Clin - GuruFocus

Jun 05, 2025

Leading Oncologists Review Breakthrough Data from Moleculin's Sarcoma Lung Metastases Trial - Stock Titan

Jun 05, 2025

Moleculin announces efficacy results from trial of Annamycin for STS lung mets - Yahoo Finance

Jun 05, 2025

Jun 04, 2025

Moleculin Reports Positive Topline Efficacy Results from U.S. Ph - GuruFocus

Jun 04, 2025

Moleculin Biotech Shares Slump After Phase 1b/2 Trial of Annamycin Fails to Show Complete Responses - MarketScreener

Jun 04, 2025

Moleculin Biotech (MBRX) Reports Promising Phase 1B/2 Trial Resu - GuruFocus

Jun 04, 2025

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) | MBRX Stock News - GuruFocus

Jun 04, 2025

Moleculin Biotech Reports Promising Efficacy Results for Annamycin in Phase 1B/2 Trial for Soft Tissue Sarcoma Lung Metastases - Nasdaq

Jun 04, 2025

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) - GlobeNewswire

Jun 04, 2025

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) - GlobeNewswire Inc.

Jun 04, 2025

Breakthrough: Moleculin's Cancer Drug Achieves 59.4% Clinical Benefit Rate in Late-Stage Trial - Stock Titan

Jun 04, 2025

Jun 02, 2025

Roth Capital Partners Manages New Developments for Moleculin Biotech (MBRX) | MBRX Stock News - GuruFocus

Jun 02, 2025

Roth Capital Partners Manages New Developments for Moleculin Bio - GuruFocus

Jun 02, 2025

May 23, 2025

Moleculin receives Nasdaq non-compliance notice By Investing.com - Investing.com South Africa

May 23, 2025

Moleculin Biotech Faces Nasdaq Non-Compliance Notice - TipRanks

May 23, 2025

Moleculin receives Nasdaq non-compliance notice - Investing.com

May 23, 2025

May 19, 2025

Moleculin signals first 45-patient unblinding for Phase 3 AML trial by end of 2025 as key regulatory milestones achieved - MSN

May 19, 2025

May 17, 2025

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 15, 2025